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Abstract
Background: The aim of our study was to assess psychiatric symptoms in patients with genetically proven primary
mutation of the mitochondrial DNA.
Methods: 19 adults with known mitochondrial mutation (MT) have been assessed with the Stanford Health
Assessment Questionnaire 20-item Disability Index (HAQ-DI), the Symptom Check List-90-Revised (SCL-90-R), the
Beck Depression Inventory-Short Form (BDI-SF), the Hamilton Depression Rating Scale (HDRS) and the clinical
version of the Structured Clinical Interview for the the DSM-IV (SCID-I and SCID-II) As control, 10 patients with
hereditary sensorimotor neuropathy (HN), harboring the peripheral myelin protein-22 (PMP22) mutation were
examined with the same tools.
Results: The two groups did not differ significantly in gender, age or education. Mean HAQ-DI score was 0.82 in
the MT (range: 0-1.625) and 0.71 in the HN group (range: 0-1.625). Level of disability between the two groups did
not differ significantly (p = 0.6076). MT patients scored significantly higher on the BDI-SF and HDRS than HN
patients (12.85 versus 4.40, p = 0.031, and 15.62 vs 7.30, p = 0.043, respectively). The Global Severity Index (GSI) of
SCL-90-R also showed significant difference (1.44 vs 0.46, p = 0.013) as well as the subscales except for
somatization. SCID-I interview yielded a variety of mood disorders in both groups. Eight MT patient (42%) had past,
6 (31%) had current, 5 (26%) had both past and current psychiatric diagnosis, yielding a lifetime prevalence of 9/19
(47%) in the MT group. In the HN group, 3 patients had both past and current diagnosis showing a lifetime
prevalence of 3/10 (30%) in this group. SCID-II detected personality disorder in 8 MT cases (42%), yielding 3
avoidant, 2 obsessive-compulsive and 3 personality disorder not otherwise specified (NOS) diagnosis. No
personality disorder was identified in the HN group.
Conclusions: Clinicians should be aware of the high prevalence of psychiatric symptoms in patients with
mitochondrial mutation which has both etiologic and therapeutic relevance.
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Background
Mitochondrial disorders are metabolic conditions with
chronic deterioration and multiple organ involvement.
Primary mutations of the mitochondrial DNA (mtDNA)
are inherited maternally while mitochondrial diseases
due to mutations in nuclear DNA are transmitted as
mendelian traits. The ratio of heteroplasmy (ratio of the
mutant and wild type mtDNA) and threshold level (the
proportion of mutated mitochondria required to cause
dysfunction) varies from tissue to tissue, resulting in a
wide variety of clinical phenotypes [1]. Some presenta-
tions of mtDNA mutations are clustered into syndromes
such as MELAS (mitochondrial encephalomyopathy lac-
tic acidosis and stroke-like episodes) or CPEO (chronic
progressive external ophthalmoplegia), but most of them
show great heterogeneity. In the background of the late
onset and the progression of some mtDNA disorders
there is good evidence for increases in the proportion of
some pathogenic mutations - including pathogenic large
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scale deletions and tRNA point mutations - with age in
skeletal muscle, however this is not a general phenom-
enon [2]. The inability to increase ATP production at
times of higher energy demand explains why clinical
symptomatology typically occurs in association with
physiological [3] or psychological [4] stressors.
Brain tissue depends to a large extent on mitochon-
drial function for its metabolism, including the mainte-
nance of the transmembrane potential [5], calcium
homeostasis [6], signal transduction [7] and synaptic
plasticity [8]. Therefore, impairments in oxidative phos-
phorylation tend to manifest in neurologic, psychiatric
or neuropsychologic symptomatology [9].
There is a growing number of evidence for the asso-
ciation of mitochondrial dysfunction and psychiatric ill-
nesses both in vitro and in vivo. Morphological changes
[10], altered cellular location [11], decreased number
[12] and function [13] of mitochondria has been found
in diverse psychiatric conditions. Downregulation of
mtDNA genes [14,15], reduced expression profiles of
electron transport chain subunits [3,15], impaired
defense against oxidative stress [16] and an overall dys-
function of brain metabolism at mitochondrial level [17]
has also been described in association with psychiatric
disorders.
While many case report suggests the new era of ‘mito-
chondrial psychiatry’ [18], a PubMed search yielded only
one study where psychiatric assessment has been carried
out systematically with an adult patient population
selected by the presence of major and minor criteria of
mitochondrial disease [19]. The aim of our study was to
assess psychiatric symptoms in a cohort of patients with
genetically proven primary mtDNA mutations which to
our knowledge has not yet been performed.
Methods
Patients
Nineteen patients with primary mutation of the mtDNA
were evaluated (MT patients, Patient 1-19, 13 female, 6
male). Mean age for the 13 probands, included in the
statistical analysis was 34 ± 8.43 years (male: μ = 27.25,
s = 6.8; female: μ = 36.66, s = 7.65), average years of
education was 12.84 ± 1.21 years (male: μ = 13.25, s =
1.5; female: μ = 12.66, s = 1.12). As control, 10 patients
(HN patients, Patient 20-29, 4 female, 6 male, mean age:
40 ± 10.99, average years of education: 14.2 ± 3.85
years) with hereditary sensorimotor neuropathy were
examined. Diagnosis was based on clinical features sup-
ported by the presence of primary mtDNA mutations in
MT patients and by the presence of the PMP22 gene
mutation in HN patients.
All participants of the study were Caucasian and vis-
ited the clinic within 1 year. Written, informed consent
was obtained from all participants. This study was
carried out according to the Helsinki Declaration and
was approved by the Research and Ethics committee of
Semmelweis University.
Neurological and psychiatric assessment
Neurological assessment was carried out with all MT
and HN patients. Functional ability was assessed using
the Hungarian validated version of the Stanford Health
Assessment Questionnaire 20-item Disability Index
(HAQ-DI) [20]. Detailed psychiatric assessment used the
Symptom Checklist-90-Revised (SCL-90-R) [21], the
Beck Depression Inventory-Short Form (BDI-SF) [22]
self report inventories as well as the clinician-adminis-
tered 21-item Hamilton Depression Rating Scale
(HDRS) [23] and the clinical version of the Structured
Clinical Interview for the DSM-IV axis-I (SCID-I) [24]
and axis-II disorders (SCID-II) [25].
The SCL-90-R helps evaluate a broad range of psycho-
pathological symptoms. It yields 9 scores of primary
symptom dimensions (somatization, obsession-compul-
sion, interpersonal sensitivity, depression, anxiety,
hostility, phobic anxiety, paranoid ideation and psychoti-
cism), an additional item subscale referring to sleep and
memory problems and the arithmetic mean of all of the
above, the global severity index (GSI). The BDI-SF is a
13-item questionnaire scored on a 4-point scale, from 0
to 3, with overall scores ranging from 0 to 39. The BDI-
SF has been found to have a good correlation with the
standard 21-item BDI (r = 0.96, p = 0.001) and relates
the clinical depth-of-depression (r = 0.61) [22]. The
emphasis of the 21-item HDRS is on melancholic and
physical symptoms of depression. In order to control for
the confounding effect of cognitive impairment, we
included patients with an IQ of 70 and above, as
assessed by the Hungarian validated version of the
Wechsler Adult Intelligence Scale (WAIS-III-R version).
Scales and interviews were administered by trained clini-
cians. Patient charts were also reviewed.
Statistical analysis
The Shapiro-Wilk test was employed to test for normal-
ity of the data (data not shown). Mann-Whitney U-test
was performed, p-values were corrected by the Holm-
Bonferroni method. All tests were two tailed and p
values ≤ 0.05 were deemed significant. Differences
between the two groups were assessed using Chi-Square
test (gender) and t-test (age and education). SCL-90-R
was analysed with SAS System for Windows (Release
9.1 TS Level 1 M3, Statistical Analysis System, SAS-
Institute USA). Correlation of total scores in GSI, BDI
and HDRS with HAQ-DI in both groups was evaluated
using Pearson’s correlation. Independent variables could
be obtained selecting only the proband (index case)
from each family from the cohort of MT patients. HN
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patients were all unrelated, statistics were thus per-
formed using data from 13 MT (Patient 1, 2, 3, 5, 8, 10,
11, 13, 14, 15, 16, 18, 19) and 10 HN patients.
Genetic analysis
DNA was extracted from blood cells. In cases with high
suspicion of mitochondrial dysfunction where no muta-
tion was found in blood cells, skeletal muscle biopsy
was performed by Qiagen DNA extraction kit according
to the manufacturer’s instructions and previously pub-
lished method [26]. Samples were screened at the most
frequently mutated sites (’hot spots’, mtDNA ‘common
mutations’; A3243G, A8344G, A8356G, T8993C,
T8993G) with PCR-RFLP using standard methods. For
the mtDNA ‘common deletion’ (a 4977 base-pair dele-
tion between nucleotides 8470 and 13447), long-PCR
methodology was used. In cases where no common
mutation was found, the entire mtDNA was sequenced
using standard methods. The PMP22 deletion and dupli-
cation was detected with real time PCR as published
earlier [27]. The 5HTTLPR (serotonin-transporter-
linked polymorphic region) genotypes of both MT and
HN patients were detected by previously reported
method [28].
Results and Discussion
Genotypes and clinical assessment
The two groups did not differ significantly in gender
(Chi-square value = 1.9652; p value = 0.1610), age (t-
value = -1.42; p value = 0.1711) or education (t-value =
-1.20; p value = 0.243). Ten MT patients had common
mutation of mtDNA. Four of them (Patient 1-4) har-
bored the A3243G base substitution in the tRNALeu
resulting in MELAS syndrome (mitochondrial encepha-
lopathy, lactic acidosis, stroke-like episodes), four
patients (Patient 5-8) had the A8344G substitution in
tRNALys. This mutation frequently causes MERRF (myo-
clonic epilepsy associated with ragged red fibers) syn-
drome. Patient 9 and 10 harbored the T8993G mutation
in gene mitochondrial ATP synthase 6 gene which
results in NARP syndrome (neuropathy, ataxia, retinitis
pigmentosa), and four patients (Patient 11, 12, 13, 18)
had common deletion of the mtDNA. MtDNA common
deletion results in adult CPEO. Patient 14 had the
A8332G base substitution in the tRNALys and Patient 15
had the A12770G substitution resulting in a Glu - Gly
substitution in gene ND5. In case of Patient 16 and 17,
a C-T base substitution at nucleotide 14771 was present
resulting in Pro-Ser substitution in CYB gene. In the
case of Patient 19 - beside the A2706G polymorphism
which is responsible for linezolid-induced severe lactic
acidosis - 14 single nucleotide polymorphisms associated
with Leber Hereditary Optic Neuropathy (LHON) were
present potentially exerting synergistic effect.
Medication for the mitochondrial disease comprised of
Coenzyme Q10, Vitamin E and vitamin C [29]. Some
patients were taking psychiatric drugs at the time of the
assessment. Monotherapies were clonazepam (Patient 7,
10, 14), sertraline (Patient 12), mirtazapine (Patient 13),
aripiprazole (Patient 19), combination therapies were
quetiapine and trazodone for Patient 16, clonazepam,
sertraline and quetiapine for Patient 18. Anticonvulsant
treatment was valproate for Patient 7 and 8, carbamaze-
pine for Patient 14 and lamotrigine for Patient 16.
MtDNA and 5HTTLPR genotypes, clinical symptoms
and medication of the MT group are summarized in
Table 1.
In the HN group, 9 patients harbored a duplication
(Charcot-Marie-Tooth phenotype, CMT), and one
patient had a deletion (Hereditary Neuropathy with Lia-
bility to Pressure Palsy phenotype, HNPP) in the PMP22
gene.
PMP22 and 5HTTLPR genotypes, clinical symptoms
and medications of the HN group are summarized in
Table 2.
Mean HAQ-DI score was 0.82 in the MT (range: 0-
1.625) and 0.71 in the HN group (range: 0-1.625). Level
of disability between the two groups did not differ sig-
nificantly (p = 0.6076).
Psychiatric assessment
Significant difference was found in the GSI score (1.44 vs
0.46, p = 0.013) and the nine subscales of the SCL-90-R
scale. These subscales were obsession-compulsion (p =
0.0079), interpersonal sensitivity (p = 0.0079), depression
(p = 0.0309), anxiety (p = 0.0309), hostility (p = 0.0428),
phobic anxiety (p = 0.0309), paranoid ideation (p =
0.0101) psychoticism (p = 0.0002) and additional items
(p = 0.013). No significant difference was found between
the two groups’ somatization score (p = 0.0817).
BDI-SF and HDRS scores of the two groups also dif-
fered significantly (12.85 vs 4.40, p = 0.0309, and 15.62
vs 7.30, p = 0.0428, respectively). No correlation has
been found between total scores of GSI, BDI and HDRS
with HAQ-DI either in the MT or in the HN group as
assessed by Pearson’s correlation.
Results of the SCL-90-R, BDI-SF, HDRS and HAQ-DI
are summarized in Table 3.
A variety of psychiatric disorders was diagnosed with
SCID-I, with a current diagnosis in 6 (31%), past diagno-
sis in 8 (42%), both past and current diagnosis in 5
(26%), a lifetime prevalence in 9 (47%) MT cases. Past
or current major depressive disorder, dysthymia, bipolar
II and adjustment disorder with depressed mood
occurred in 2 MT cases while the past or current diag-
nosis of major depression with psychotic features, bipo-
lar I, mixed anxiety-depressive disorder, postpartum
depression and PTSD was explored in 1 MT case.
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Eight MT patients were diagnosed with personality
disorder representing 42% of the group. Three cases of
avoidant and 2 cases of obsessive-compulsive personality
disorder were diagnosed. In 3 cases, personality disorder
not otherwise specified (NOS) was described referring
to depressive personality in case of Patient 5 and mixed
personality disorder in the cases of Patient 16 and 18.
Five MT patients (Patient 1, 5, 8, 16, 18) had both Axis
I and II diagnosis. This subgroup also had mean BDI and
GSI scores above the average of the entire MT group
(BDI of 19.2 versus 12.85 and GSI of 2.29 versus 1.44).
Patient 5, 6, 9, 11, 12, 17 was free of somatic symp-
toms (indicated with a HAQ-DI score of 0) but only
Patient 6 and 12 was free of psychiatric symptoms as
Table 1 MtDNA and 5TTLPR genotypes, clinical symptoms and medication of MT patients
ID mtDNA mutation 5HTTLPR
genotype
Symptoms Medication
(with total daily dose)
1 A3243G MELAS L/S Hypoacusis, ataxia, myopathy, endocrine
dysfunction
-
2 A3243G MELAS L/S Ataxia -
3 A3243G MELAS L/S CPEO, myopathy (mother of Patient 4) -
4 A3243G MELAS L/S CPEO -
5 A8344G MERRF L/L Migraine -
6 A8344G MERRF S/S Mild tremor in the upper limbs (mother
of Patient 7 and 8)
-
7 A8344G MERRF S/S Myoclonus epilepsy, thrombocytopenia
(twin brother of Patient 8)
levetiracetam (1000 mg), clonazepam (2 mg), valproate (1500 mg),
vinpocetine (20 mg)
8 A8344G MERRF S/S Myoclonus epilepsy, ataxia, cognitive
dysfunction, thrombocytopenia (twin
brother of Patient 7)
levetiracetam (2500 mg), valproate (2100 mg), vinpocetine (90 mg),
trimetazidine (40 mg), betaxolol (10 mg), atorvastatine (10 mg),
allopurinol (200 mg)
9 T8993G NARP L/S Developmental abnormality of the right
arm, hypothyreosis, (mother of Patient 10)
-
10 T8993G NARP L/L NARP clonazepam (1mg)
vinpocetine(10 mg)
11 mtDNA del L/L CPEO, iron-deficient anemia,
hypercholesterolemia
-
12 mtDNA del L/S Myalgia, exercise intolerance sertraline (50 mg)
13 mtDNA del L/S Kearns-Sayre syndrome clonazepam (1mg)
vinpocetine (20 mg)
mirtazapine (30mg)
14 A8332G
C8270T
L/S Dystonia, early onset stroke-like symptoms levetiracetam (1000mg),clonazepam (1.25mg)
carbamazepine (1000mg)
15 A12770G L/S Ataxia, hypoacusis, spastic paraparesis -
16 A15326G
A750G
A1438G
A8860G
A15326G
L/L Hypoacusis, limb tremor, myalgia, apraxia
(mother of Patient17)
trimetazidine (60 mg), metformin (850 mg), bisoprolol (5mg),
quetiapine (400 mg), lamotrigine (50 mg), trazodone (300mg)
17 see
Patient 16.
L/L - -
18 A3720G
G3849A
T13020C
T13734C
A12308G
T8473C
L/S Severe cardiomyopathy, cognitive
dysfunction
trimetazidine (40 mg), enalapril (5 mg), molsidomine (4 mg),
quetiapine (400 mg), lamotrigine (100 mg), sertraline (100 mg),
clonazepam (1.5 mg)
19 C14766T
G709A
A73G
T16126C
S/S Peripheral neuropathy tolperisone (300 mg), aceclofenac (200 mg), aripiprazole (15 mg),
duloxetine (30 mg), clonazepam (1 mg)
Italics indicate probands (unrelated patients; independent variables) included in the statistical analysis
Abbreviations; mtDNA del deletion of the mtDNA. MELAS mitochondrial encephalopathy, lactic acidosis, stroke-like events; CPEO chronic progressive external
ophthalmoplegia; MERRF myoclonic epilepsy with ragged red fibers; NARP neuropathia, ataxia, retinitis pigmentosa. 5HTTLPR: serotonin-transporter-linked
polymorphic region; S/S genotype: short-short homozygous; L/L genotype: long-long homozygous; L/S genotype: long-short heterozygous
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well (although Patient 12 was on Sertraline 50 mg at the
time of the assessment for subclinical anxiety). From
this physically asymptomatic group Patient 5 and 11 was
included in the statistical analysis (independent vari-
ables). They have higher BDI (15.5 versus 12.85) and
GSI (1.66 versus 1.44) compared to the entire MT
group.
Gender, age, results of the SCID interviews, together
with the BDI-SF, GSI and HAQ-DI scores of the MT
group are indicated in Table 4.
In the HN group, 3 patients (30%) had past and cur-
rent psychiatric diagnosis. Two HN patients had lifetime
prevalence of dysthymia, 1 HN patient had lifetime pre-
valence of major depression, bipolar II, adjustment
Table 2 PMP22 and 5HTTLPR genotypes, clinical symptoms and medication of HN patients (control group)
ID PMP22 mutation 5HTTLPR
genotype
Symptoms Medication
(with total daily
dose)
20 PMP22 duplication L/L Mild atrophy of the hand and feet muscles -
21 PMP22 duplication L/L Pes equinovarus, moderate paresis in the distal muscles of the legs -
22 PMP22 deletion S/S Sensory disturbancies in the lower limbs, neuropathy to pressure palsy -
23 PMP22 duplication S/S Generalized muscle weakness, walking difficulty, distal type hypesthesia in the
limbs, excavated feet
pregabalin (300 mg)
duloxetine (30 mg)
24 PMP22 duplication L/S Paresthesia, distal type hypesthesia in the limbs, muscle cramps, gait instability -
25 PMP22 duplication L/S Distal type muscle weakness in the limbs, tremor in the hands chlordiazepoxide
(5 mg)
tolperisone (150 mg)
propranolol (40 mg)
26 PMP22 duplication L/S Excavated feet, moderate distal paresis of the limbs, ataxia -
27 PMP22 duplication S/S Mild paresis in the hand and feet muscles -
28 PMP22 duplication S/S Moderate distal weakness of the limbs, distal type hypesthesia, head tremor, gait
instability. Associated disorders: diabetes mellitus, hyperlipidaemia
duloxetine (60 mg)
gabapentin (600 mg)
rosuvastatine (20 mg)
ezetimibe (10 mg)
29 PMP22 duplication L/L Moderate atrophy and paresis in the hand and feet muscles, gait instability.
Associated disorder:
asthma bronchiale
-
Abbr.: PMP22 peripheral myelin protein-22; 5HTTLPR: serotonin-transporter-linked polymorphic region; S/S genotype: short-short homozygous; L/L genotype: long-
long homozygous; L/S genotype: long-short heterozygous
Table 3 Comparison of SCL-90-R, BDI-SF, HDRS and HAQ-DI scores of MT and HN patients
MT group HN group t-value df D p value (Raw) p value (Adjusted)
Measured items mean SD mean SD
GSI 1.44 0.91 0.46 0.53 3.64 21 1.587 0.0015 0.0130*
Somatization 1.77 1.10 0.98 0.83 1.83 21 0.798 0.0817 0.0817
Obsessive-compulsive 1.65 1.04 0.47 0.68 3.99 21 1.743 0.0007 0.0079*
Interpersonal sensitivity 1.55 0.97 0.40 0.51 3.99 21 1.740 0.0007 0.0079*
Depression 1.90 1.21 0.75 1.03 3.12 21 1.362 0.0052 0.0309*
Anxiety 1.32 1.14 0.42 0.63 3.19 21 1.392 0.0044 0.0309*
Hostility 1.26 1.00 0.48 0.50 2.60 21 1.133 0.0169 0.0428*
Phobia 1.14 1.11 0.29 0.56 3.06 21 1.335 0.0060 0.0309*
Paranoia 1.42 1.05 0.28 0.39 3.81 21 1.665 0.0010 0.0101*
Psychoticism 0.92 0.60 0.13 0.24 5.65 21 2.465 <.0001 0.0002*
Additional items 1.48 0.96 0.43 0.66 3.66 21 1.599 0.0014 0.0130*
BDI-SF 12.85 8.33 4.40 5.36 3.18 21 1.386 0.0045 0.0309*
HDRS 15.62 8.62 7.30 5.52 2.67 21 1.166 0.0143 0.0428*
HAQ-DI 0.82 0.59 0.71 0.59 0.52 21 0.228 0.6076 0.6076
Abbr.: SCL-90-R Symptom Checklist-90-Revised; GSI global severity index; BDI Beck Depression Inventory-Short Form; HDRS Hamilton Depression rating Scale, HAQ-
DI Stanford Health Assessment Questionnaire Disability Index. D: Cohen’s d effect size, Adjusted_p: p values with Bonferroni-Holm correction. Asterisks refer to
statistically significant differences (p ≤ 0.05) between the two groups.
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disorder with depressed mood and alcohol abuse. No
personality disorder was found. Somatically asympto-
matic (HAQ-DI score of 0) HN patients were Patient 20
and 27 with a lower mean BDI and GSI than the HN
group’s average (0.5 versus 4.4 and 0.11 versus 0.46,
respectively).
Gender, age, results of the SCID interviews, together
with the BDI-SF, GSI and HAQ-DI scores of the HN
group are shown in Table 5.
Discussion
This is the first systematic study investigating psychiatric
symptoms in a well-defined cohort of patients with
genetically proven mtDNA-related mitochondrial disor-
ders compared to a homologous patient group with
genetically determined debilitating neuromuscular dis-
ease. Comparable levels of disability are suggested by
similar mean HAQ-DI and SCL-90-R somatization
scores. Our data revealed a higher prevalence of psy-
chiatric symptoms, especially various mood disorders in
the MT group supporting the hypothesis that mitochon-
drial dysfunction of the central nervous system may play
a role in the pathogenesis of different psychiatric
spectrum disorders, including depressive disorders [30].
MtDNA point mutations [31] and deletions [32] have
been previously associated with major affective disease.
The MR-spectroscopy literature supports the presence
of brain metabolic alterations in bipolar disorder with
variable relationships to the mood state [33]. Mitochon-
drial dysfunction may alter the signaling of hippocampal
neurons via calcium-dependent mitochondrial superox-
ides, modulating nuclear cAMP-responsive element-
binding protein (CREB) phosphorylation [34], which
may play an important role in mood modulation [35]. In
our study both the BDI-SF and HDRS scores were sig-
nificantly higher in the MT group. SCID-I interview in
the MT group yielded a high prevalence of mood disor-
ders as well. The fact that SCID-I did not detect mood
disturbance in some patients with moderately high BDI-
SF scores likely reflects that patients generally tend to
admit more symptoms on a self-inventory questionnaire
than on an interview. Also, despite distinguished screen-
ing and diagnostic cutoff scores for the BDI-SF [36] it is
important to note that a high score can be added up
from a few items and does not necessarily mean that
the patient actually have depression. The BDI-SF
Table 4 Gender, age, results of SCID-I and SCID-II, BDI-SF, GSI and HAQ-DI scores of MT patients
ID Gender Age Past diagnosis
SCID I.
Current diagnosis SCID I. Personality disorder SCID
II.
BDI GSI HAQ-
DI
1 F 34 Mixed anxiety-depressive disorder Major depressive disorder Avoidant 22 1.92 1.375
2 F 51 Dysthymia - - 8 1.09 0.875
3 F 34 - - - 8 1.09 1.25
4 F 16 - - - 14 1.24 0.125
5 M 32 - Dysthymia Personality disorder NOS 21 2.46 0
6 F 61 - - - 0 0.33 0
7 M 34 Adjustment disorder with depressed
mood
- - 2 0.31 0.375
8 M 34 Adjustment disorder with depressed mood - Avoidant 3 0.87 1.625
9 F 59 - - Obsessive - compulsive 8 0.59 0
10 M 23 - - - 7 0.44 1.375
11 F 34 - - - 10 0.86 0
12 F 40 - - - 2 0.22 0
13 F 38 Bipolar II disorder Bipolar II, current episode
depressive
- 16 1.19 0.375
14 M 20 - - - 4 0.78 0.125
15 F 22 - - Obsessive - compulsive 5 0.74 1.625
16 F 39 Major depression with psychotic features Major depressive disorder Personality disorder NOS 30 3.02 0.625
17 M 20 - - Avoidant 2 0.25 0
18 F 37 PTSD Bipolar II, current episode
depressive
Personality disorder NOS 20 3.2 0.625
19 F 41 Postpartum depression Bipolar I. latest episode depressive - 13 1.08 0.75
Italics indicate probands (unrelated patients; independent variables) included in the statistical analysis.
Abbr.: M male, F female, SCID structured clinical interviews for the DSM-IV; Personality disorder NOS: personality disorder not otherwise specified; BDI-SF Beck
Depression Inventory Short Form, SCL-90-R Symptom Checklist revised; GSI global severity index, HAQ-DI Stanford Health Assessment Questionnaire 20-item
Disability Index; PTSD posttraumatic stress disorder
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includes cognitive-affective but not somatic items to
avoid spuriously high scores and overreporting of
depression in somatic patients [37]. Instruments mea-
suring both cognitive, affective, somatic, and behavioral
symptoms of depression are more accurate for diagnos-
ing major depression [37]. The BDI-SF should be
regarded as an initial screening instrument and a sever-
ity index of depression in patients with multisystemic
symptomatology.
The short-short (s/s) homozygous length polymorph-
isms of the 5HTTLPR has been implied in the genetic
background of depression [38]. Although the association
is not straightforward [39] and has been questioned
[40], the 5HTTLPR is still widely studied in the develop-
ment of neuroticism and depression [41]. In our study,
those having high levels of depression in the MT group
did not harbor the s/s homozygous polymorphism.
Although the SCL-90-R is not a diagnostic scale, sig-
nificant differences found between nine SCL-90-R sub-
scale scores suggest that MT patients are more prone to
a variety of psychiatric problems. Subscales with highly
significant differences were obsessive-compulsive symp-
toms, interpersonal sensitivity and psychoticism.
Personality disorders were also highly represented in
the MT group, the most prevalent was avoidant personal-
ity. Avoidant personality traits have been described with
mtDNA mutations [42]. It possibly reflects the fact that
some mitochondrial patients are symptomatic early in
childhood predisposing them to peer rejection and its
long-term psychological consequences. Avoidance can
also become a survival skill when one is not able to keep
up with peers, e.g., at running as fast as other children,
or being more easily fatigued. Obsessive personality disor-
der was present in 2 MT cases. In a previous report a
case of MELAS syndrome coexisting with obsessive-com-
pulsive disorder was presented where the patient had a
‘perfectionistic and obsessional’ premorbid personality
[43]. The highly significant (p = 0.0079) SCL-90-R obses-
sive-compulsive subscale score implies that MT patients
are generally more prone to obsessive-compulsive symp-
tomatology. Eight of our 19 MT patients were diagnosed
with personality disorder which is a high prevalence
(42%). Those diagnosed with both axis I and II disorder
also scored higher on the BDI and GSI. Relevant litera-
ture is scarce; mostly ‘organic personality change’ - due
to the gradual cognitive and emotional decline - has been
described [17]. Further studies are needed to clarify the
association between the pathomechanism of personality
disorders and mitochondrial cytopathies.
Although correlation between somatic and psychiatric
symptoms was not found in either group, we demon-
strated that physically asymptomatic HN patients score
lower than their groups on the BDI and GSI, but not
physically asymptomatic MT patients. It was also pre-
sented that the physically and psychiatrically asympto-
matic subgroups of the MT cohort had little overlap.
According to these results, psychiatric and somatic
symptoms do not necessarily co-occur in the MT group
implying that psychiatric symptoms might be indepen-
dent manifestations of mitochondrial dysfunction and
not the consequence of the chronic somatic disease.
Psychiatric symptoms of these patients tend not to have
a classic course [19]. They are frequently treatment-
resistant and may even get worse when treated with psy-
chotropic medications. Valproic acid, for instance, is
known to interfere with beta-oxidation and is consid-
ered to be a mitochondrial toxin [44]. Drug-naivity of
our patients could not be achieved due to ethical rea-
sons. Despite diverse medication - also psychotropic
medication - we depicted many psychiatric symptoms
possibly due to treatment resistance, the complex meta-
bolic alteration in the background.
Table 5 Gender, age, results of SCID-I and SCID-II, BDI-SF, GSI and HAQ-DI scores of HN patients
ID Gender Age Past diagnosis SCID I Current diagnosis SCID I Personality disorder
SCID II
BDI GSI HAQ-DI
20 M 41 - - - 1 0.22 0
21 M 17 - - - 1 0.32 0.125
22 M 49 Adjustment disorder with depressed mood Dysthymia - 11 1.3 0.375
23 F 33 - - - 2 0.18 0.875
24 M 34 - - - 2 0.12 0.5
25 F 46 - - - 2 0.26 1.25
26 F 31 - - - 11 0.37 1.125
27 M 42 - - - 0 0 0
28 F 55 Major depressive disorder Dysthymia - 14 1.59 1.25
29 M 47 Alcohol abuse Bipolar II, latest episode hypomanic - 0 0.25 1.625
Abbr: M male, F female, SCID structured clinical interview for the DSM-IV; BDI-SF Beck Depression Inventory Short Form; SCL-90-R Symptom Checklist Revised; GSI
global severity index, HAQ-DI Stanford Health Assessment Questionnaire 20-item Disability Index
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Conclusions
We detected a high prevalence of psychiatric symptoms
in patients with mtDNA disorders. The early identifica-
tion of these patients is important in order to avoid
adverse effects of experimental psychotropic pharma-
cotherapy and to slow the progression of the mitochon-
drial disease by administering coenzyme Q10 and free
radical scavengers. If the proband is diagnosed, maternal
relatives and siblings can also be treated at an early
phase. Further systematic studies are required to clarify
the association of mitochondrial and psychiatric disorders
and to improve diagnostics as well as therapeutics for
these patients in the new era of personalized medicine.
Limitations
Our study had several methodological limitations; we
examined small number of patients because primary
mtDNA-related mitochondrial diseases are relatively
rare and often underdiagnosed. Due to this small patient
number, statistical significances have limited strength.
We examined families therefore statistical analysis could
only involve probands to keep variables independent.
Some of our patients were on psychiatric medication at
the time of the assessment which could potentially bias
our results. Medication was not included into statistics
neither as variable due to the high diversity of drugs
used nor as a factor with 2 levels because dividing these
small patient groups into subgroups would have further
weakened our results. The presented results may not
generalize to all patients with mitochondrial disorders.
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